General Catalyst, one of Silicon Valley's largest capital firms, is gearing up to launch what’s known as a “continuation fund” worth between $800 million and $1 billion, according to a ...

Ribbon had raised $55 million overall from investors that include Andreessen Horowitz, General Catalyst, and Rock Health. For its part, H1 has raised around $200 million and was last valued ...

One exception is General Catalyst, which has invested in later rounds through companies such as Commure, Transcarent and Hippocratic AI. In October, the company announced it had raised $8 billion ...

The settlement aligns with expectations that Catalyst would maintain its patent protection for Firdapse through at least May 26, 2034, and is seen as a positive development for the company.

BofA keeps a Buy rating on Catalyst Pharmaceuticals (CPRX) with a $30 price target following the announcement of a Firdapse patent settlement with a key generic challenger Teva (TEVA). Teva was ...

CORAL GABLES, Fla., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical ...

Machine learning (ML) models have recently become popular in the field of heterogeneous catalyst design. The inherent complexity of the interactions between catalyst components is very high ...